Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Excel Industries Limited (EXCELINDUS.NS)
Mumbai, IN
Established in 1941 and headquartered in Mumbai, India, Excel Industries Limited conducts business both domestically and internationally, focusing on the production and sale of a diverse array of chemicals, pharmaceutical precursors, and ecological solutions. The company's chemical portfolio includes offerings for industrial, specialty, and mining sectors; vital agrochemical components; specific products like casscel; various phosphorus derivatives; biocides and phosphonates; along with essential polymer inputs and specialized monomers. In its environmental segment, Excel provides soil enhancers, organic pesticides, and other bio-based items. Additionally, it manufactures critical penultimate pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and veterinary APIs. The company also engages in financial ventures.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.30% | +1.67% | +7.07% | +4.62% | +6.97% | +6.41% | -11.37% | +17.81% | -12.65% | +258.10% | +941.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%+11.9% ★ Q1'26: +13.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-11.2% Q1'26: -0.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+0.5% Q1'26: -6.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+6.7% Q1'26: +4.4% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+3.6% Q1'26: +2.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.1% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.07× ★ Q1'26: 0.09× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 1996 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.01B
est.
|
4.82B
est: 4.99B (-3.5%)
|
4.49B
est: 5.37B (-16.4%)
|
4.61B
est: 4.58B (+0.5%)
|
5.97B
est: 5.42B (+10.2%)
|
8.18B
est: 8.61B (-4.9%)
|
7.00B
est: 9.03B (-22.5%)
|
7.44B
est: 10.02B (-25.7%)
|
9.78B
est: 4.99B (+96.0%)
|
5.37B
5.37B – 5.37B
+7.5% YoY
|
4.58B
4.58B – 4.58B
-14.6% YoY
|
5.42B
5.42B – 5.42B
+18.2% YoY
|
8.61B
8.61B – 8.61B
+58.9% YoY
|
9.03B
9.03B – 9.03B
+4.9% YoY
|
10.02B
10.02B – 10.02B
+11.0% YoY
|
| EBITDA |
444.34M
est.
|
776.76M
est: 736.46M (+5.5%)
|
635.96M
est: 791.85M (-19.7%)
|
500.57M
est: 676.48M (-26.0%)
|
1.27B
est: 799.36M (+59.3%)
|
2.54B
est: 1.27B (+100.2%)
|
1.41B
est: 1.33B (+5.8%)
|
1.30B
est: 1.48B (-12.0%)
|
1.49B
est: 736.46M (+102.8%)
|
791.85M
791.85M – 791.85M
+7.5% YoY
|
676.48M
676.48M – 676.48M
-14.6% YoY
|
799.36M
799.36M – 799.36M
+18.2% YoY
|
1.27B
1.27B – 1.27B
+58.9% YoY
|
1.33B
1.33B – 1.33B
+4.9% YoY
|
1.48B
1.48B – 1.48B
+11.0% YoY
|
| EBIT |
345.29M
est.
|
629.77M
est: 572.29M (+10.0%)
|
482.01M
est: 615.33M (-21.7%)
|
357.46M
est: 525.68M (-32.0%)
|
1.12B
est: 621.17M (+80.4%)
|
2.36B
est: 986.85M (+139.3%)
|
1.18B
est: 1.04B (+14.1%)
|
1.03B
est: 1.15B (-10.4%)
|
1.15B
est: 572.29M (+101.5%)
|
615.33M
615.33M – 615.33M
+7.5% YoY
|
525.68M
525.68M – 525.68M
-14.6% YoY
|
621.17M
621.17M – 621.17M
+18.2% YoY
|
986.85M
986.85M – 986.85M
+58.9% YoY
|
1.04B
1.04B – 1.04B
+4.9% YoY
|
1.15B
1.15B – 1.15B
+11.0% YoY
|
| Net Income |
301.23M
est.
|
411.80M
est: 437.17M (-5.8%)
|
260.44M
est: 467.48M (-44.3%)
|
200.31M
est: 638.45M (-68.6%)
|
738.94M
est: 519.19M (+42.3%)
|
1.53B
est: 1.69B (-9.0%)
|
960.73M
est: 1.68B (-42.8%)
|
710.86M
est: 1.87B (-61.9%)
|
853.13M
est: 436.84M (+95.3%)
|
467.14M
467.14M – 467.14M
+6.9% YoY
|
637.98M
637.98M – 637.98M
+36.6% YoY
|
518.81M
518.81M – 518.81M
-18.7% YoY
|
1.68B
1.68B – 1.68B
+224.6% YoY
|
1.68B
1.68B – 1.68B
-0.3% YoY
|
1.87B
1.87B – 1.87B
+11.2% YoY
|
| SGA |
210.42M
est.
|
64.95M
est: 348.75M (-81.4%)
|
189.69M
est: 374.98M (-49.4%)
|
225.01M
est: 320.35M (-29.8%)
|
288.55M
est: 378.54M (-23.8%)
|
323.44M
est: 601.38M (-46.2%)
|
367.03M
est: 630.74M (-41.8%)
|
416.13M
est: 700.12M (-40.6%)
|
574.99M
est: 348.75M (+64.9%)
|
374.98M
374.98M – 374.98M
+7.5% YoY
|
320.35M
320.35M – 320.35M
-14.6% YoY
|
378.54M
378.54M – 378.54M
+18.2% YoY
|
601.38M
601.38M – 601.38M
+58.9% YoY
|
630.74M
630.74M – 630.74M
+4.9% YoY
|
700.12M
700.12M – 700.12M
+11.0% YoY
|
| EPS |
23.94
est.
|
36.77
est: 34.75 (+5.8%)
|
20.73
est: 37.16 (-44.2%)
|
15.88
est: 50.75 (-68.7%)
|
58.78
est: 41.27 (+42.4%)
|
122.07
est: 133.97 (-8.9%)
|
76.43
est: 133.52 (-42.8%)
|
56.55
est: 148.50 (-61.9%)
|
67.81
est: 34.75 (+95.1%)
|
37.16
37.16 – 37.16
+6.9% YoY
|
50.75
50.75 – 50.75
+36.6% YoY
|
41.27
41.27 – 41.27
-18.7% YoY
|
133.97
133.97 – 133.97
+224.6% YoY
|
133.52
133.52 – 133.52
-0.3% YoY
|
148.50
148.50 – 148.50
+11.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ravi Ashwin Shroff | MD & Executive Director | 49M | male |
| Hrishit Ashwin Shroff | President of Environment, Biotech Business & Corporate Services and Executive Director | 39M | male |
| Ashwin Champraj Shroff | Executive Chairman | 36M | male |
| Surendra Kumar Singhvi | Vice President of CSR, Compliance Officer & Company Secretary | 2M | male |
| Pradeep N. Ghattu | President & Chief Operating Officer | — | male |
| Balachandran | President of Chemicals Division | — | male |
| Devendra Parasmal Dosi | Chief Financial Officer | — | male |
| Sekar Bharadwaj | Associate Vice President of Human Resources | — | male |
| Siddhart Raut | General Manager of Finance & Accounts | — | male |
| Sanjay R. Sapate | Vice President of Manufacturing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EXCELINDUS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
